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Key points 28 
Question: Are variants in the C-reactive protein (CRP) gene that are known to influence 29 
circulating CRP concentration associated with late age-related macular degeneration (AMD)? 30 
Findings: We selected four CRP variants and conducted a pooled analysis of 1727 late AMD 31 
cases and 1153 controls from two hospital-based case-control studies and one cross-sectional 32 
population-based study. We found no statistical association between these CRP variants and 33 
any type of late AMD.  34 
Meaning: Circulating CRP concentration is unlikely to be causally related to AMD. 35 
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Abstract (Word count: 312) 36 
Importance: C-reactive protein (CRP) is a circulating inflammatory marker associated with 37 
late age-related macular degeneration (AMD). It remains uncertain whether the association 38 
between CRP concentration and AMD is causal.  39 
Objective: our primary objective was to assess whether CRP single nucleotide 40 
polymorphisms (SNPs) that influence circulating CRP concentration are associated with late 41 
AMD. 42 
Design, setting and participants: Participants in two UK hospital-based case-control studies 43 
(Cambridge and Moorfields) and one pan-European cross-sectional population-based study 44 
(EUREYE) were recruited between 2000 and 2006. Participants underwent dilated stereo-45 
digital fundus photography graded according to the International Classification of Age-46 
related Maculopathy and Macular Degeneration. There were 1727 cases of late AMD (1151 47 
neovascular (nvAMD), 384 geographic atrophy (GA), 192 mixed (nvAMD and GA)), and 48 
1153 controls. Early AMD cases (n=574) were included only from EUREYE. 49 
Exposure(s): Four common SNPs (rs1205, rs1130864, rs1800947, rs3093077) were selected 50 
based on demonstrated influence on circulating CRP circulation in the literature. In one study 51 
genotyping of rs3093077 failed and rs1800947 was only typed in one study.  52 
Main Outcome and Measure(s): Genetic multiplicative model for the association of SNPs 53 
with late AMD adjusted for age and sex and expressed as Odds Ratios (OR) and 95% 54 
Confidence Intervals (95% CI).  55 
Results: The mean age (SD) was 78.7 (7.4) for late AMD cases (of which 668 male, 38.7%) 56 
and 74.9 (7.0) for controls (of which 510 male, 44.2%). In the pooled results of all three 57 
studies, neither rs1205 nor rs1130864 were associated with late AMD, per allele OR=0.99 58 
(95% CI=0.86-1.14) and OR=0.96 (95% CI=0.83-1.11) respectively. Results by late AMD 59 
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phenotype were: GA, OR=0.91 (95% CI=0.74-1.13) and OR=0.94 (95% CI=0.76-1.16); 60 
nvAMD, OR=1.01 (95% CI=0.87-1.19) or OR=0.99 (95% CI=0.84-1.16). There was no 61 
association of rs3093077 and rs1800947 with late AMD or any late AMD phenotype. There 62 
were no significant findings for early AMD. 63 
Conclusions and relevance: Our results do not support a causal association between CRP 64 
concentration and AMD.    65 
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Introduction 66 
Inflammation has been recognised to play a key role in age-related macular degeneration 67 
(AMD)1,2 strengthened by the discovery of multiple genetic risk loci involved in the 68 
complement pathway.3-7 The early and intermediate stages of AMD are characterised by 69 
drusen which are accumulations of lipids and proteins that form discrete deposits under the 70 
retinal pigment epithelium, and these can both initiate and  reflect inflammatory reactions 71 
within the complement pathway.1 Several studies have investigated the relationship between 72 
circulating inflammatory markers and the onset and progression of AMD,8-12 both to 73 
understand the pathogenesis of AMD and also to assess their potential as prognostic 74 
biomarkers. One such inflammatory marker is C-reactive protein (CRP), an acute phase 75 
reactant13 which has been shown in two meta-analyses to be associated with late AMD.14,15 76 
CRP is involved in the initiation and modulation of the classical complement pathway as well 77 
as the alternative complement pathway through binding with complement factor H (CFH). 78 
Therefore it could be postulated that high concentrations of CRP have a causal role in the 79 
development of AMD by altering complement-related inflammatory responses to drusen.  80 
 81 
Demonstration of a causal role of CRP is problematic as is illustrated by the abundant work 82 
carried out on CRP and coronary heart disease (CHD). Despite the numerous studies 83 
(including many prospective studies) consistently showing an increased risk of CHD with 84 
increasing CRP,16 no studies have demonstrated an association between single nucleotide 85 
polymorphisms (SNPs) in the CRP gene and risk of CHD.17,18 This approach, described as 86 
Mendelian randomisation (MR),19 showed that, although certain CRP SNPs have been shown 87 
to influence the concentrations of circulating CRP,20 the lack of a relationship between those 88 
CRP SNPs and CHD suggests that CRP is unlikely to have a causal influence on CHD.17 A 89 
key point in the MR approach is that the causal role of a risk exposure for a specific disease is 90 
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assessed testing the relationship between genetic variants (that have been reliably shown to 91 
influence the exposure) and the disease of interest. The MR approach avoids bias due to 92 
reverse causation because genotypes are fixed at conception and therefore are not subject to 93 
confounding nor modification by the onset of disease.21 94 
  95 
Three previous studies have investigated the relationship between CRP genetic variants and 96 
AMD but none have found an association.22-24 The total number of late AMD cases in the 97 
three studies was 394 and each study may have lacked power. We investigated the 98 
relationship between AMD and CRP polymorphisms in three studies: the European Eye study 99 
(EUREYE), a cross-sectional population-based epidemiological study of AMD prevalence 100 
and risk factors,25 and two hospital-based AMD case-control studies, the Cambridge7 and 101 
Moorfields Eye Hospital (MEH)26 AMD studies.  102 
Methods 103 
For all three studies ethical approval was obtained from either national or local ethics 104 
committees and adhered to the tenets of the Declaration of Helsinki. All participants provided 105 
written informed consent to undergo the clinical examination and epidemiological data 106 
collection, and to provide a blood sample for biochemical and genetic analyses. 107 
 108 
EUREYE Study 109 
Participants were recruited between 2001 and 2002 by random sampling of the population 110 
aged 65 years and older in seven centers: Bergen (Norway), Tallinn (Estonia), Belfast 111 
(United Kingdom), Paris-Creteil (France), Verona (Italy), Thessaloniki (Greece) and Alicante 112 
(Spain). Methods have been published in full elsewhere.25 Trained field workers administered 113 
structured questionnaires including smoking, diet and sunlight exposure and self-reported 114 
 
 
7 
 
medical history. The ophthalmic examination included dilated stereo digital fundus 115 
photography. Stereo fundus images were graded at a single reading centre (Erasmus 116 
University Rotterdam) according to the International Classification of Age-related 117 
Maculopathy and Macular Degeneration27 and then categorized into five mutually exclusive 118 
grades. Grade 0 was defined as a macula free of drusen or pigmentary irregularities or with 119 
hard drusen (< 63 µm) only. Early AMD was subdivided in grade 1, defined as soft distinct 120 
drusen (≥ 63 µm) or pigmentary abnormalities, grade 2 as soft indistinct drusen (≥ 125 µm) 121 
or reticular drusen only or soft distinct drusen (≥ 63 µm) with pigmentary abnormalities, and 122 
grade 3 as soft indistinct drusen (≥ 125 µm) or reticular drusen with pigmentary 123 
abnormalities. Grade 4 was defined as presence of either neovascular AMD (nvAMD) 124 
(presence of any of the following: serous or hemorrhagic retinal or retinal pigment epithelial 125 
detachment, subretinal neovascular membrane, periretinal fibrous scar) or geographic atrophy 126 
(GA) (well-demarcated area of retinal pigment atrophy with visible choroidal vessels). In the 127 
present analysis, for reason of costs, a random sample of controls (AMD stage 0) was 128 
frequency matched on age (within a year), sex and centre with cases with (i) late AMD 129 
(nvAMD or GA) and (ii) cases with early AMD (AMD stages 2 and 3). Non-fasting venous 130 
blood samples were collected at the ophthalmological examination, separated within 4 hours 131 
of collection and serum was stored at -20⁰C for up to 4 weeks before frozen samples were 132 
transferred to a single laboratory (Queens University Belfast) for storage at -80⁰C.   133 
 134 
Cambridge AMD study 135 
The Cambridge AMD study is a case-control study of AMD with participants recruited from 136 
ophthalmic clinics in London, the South East of England and the North West of England 137 
between 2002 and 2006.7 All cases had at least one eye affected by nvAMD and/or GA. 138 
Patients were excluded if they had greater than 6 dioptres of myopic refractive error or 139 
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evidence of other inflammatory or retinovascular disease such as retinal vessel occlusion, 140 
diabetic retinopathy or chorioretinitis that could contribute to the development or confound 141 
the diagnosis of maculopathy. Almost all the controls were spouses or partners of index cases 142 
and the remainder were friends of cases. All participants described themselves as “white” 143 
rather than “other” on a recruitment questionnaire. Participants were examined by an 144 
ophthalmologist and health, lifestyle and smoking data were collected, and underwent colour 145 
stereoscopic fundus photography of the macular region. Images were graded at the Reading 146 
Centre, Moorfields Eye Hospital, London using the International Classification of Age-147 
related Maculopathy and Macular Degeneration.27 Blood was drawn at the time of interview; 148 
EDTA samples were obtained for DNA extraction, and lithium-heparin plasma samples 149 
stored at -80⁰C were later used for CRP measurements. 150 
 151 
MEH AMD study 152 
The MEH AMD study is a case-control study of AMD undertaken at Moorfields Eye 153 
Hospital, London between 2001 and 2004.26 Only cases and controls of European origin were 154 
included in the study. Cases consisted of patients attending routine follow up appointments 155 
and all new referrals from primary care clinics, casualty, and other centres with any type of 156 
AMD to try to limit any selection bias. Cases were excluded if they had retino-choroidal 157 
inflammatory disease, diabetic retinopathy, branch retinal vein or artery occlusion or any 158 
other cause of visual loss other than amblyopia. Controls were recruited from spouses or 159 
friends of cases, or were from local residential homes for the elderly within 5 miles of the 160 
hospital. Each participant was interviewed specifically for the study, and a family history, 161 
smoking history and other medical history was taken. The ophthalmic examination included 162 
Snellen acuity, slit-lamp examination and bio-microscopic funduscopy. All participants had 163 
colour stereoscopic fundus photography of the macular region and the images were graded at 164 
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the Reading Centre, Moorfields Eye Hospital, London using the International Classification 165 
of Age-related Maculopathy and Macular Degeneration.27 Controls were excluded if drusen 166 
>63um were evident. A sample of peripheral blood was obtained from each participant and 167 
stored at -20⁰C for DNA extraction and -80⁰C for analyte measurement.  168 
 169 
Circulating C-reactive protein concentration 170 
Circulating CRP concentration was measured in the EUREYE and Cambridge AMD studies. 171 
In the EUREYE study, the concentration of serum CRP was assessed by a high-sensitivity 172 
latex-enhanced turbidometric immunoassay (Wako Chemicals GmbH, Neuss, Germany) 173 
using a Cobas Fara analyzer (Roche Diagnostics, Burgess Hill, United Kingdom). In the 174 
Cambridge AMD study, the concentration of plasma CRP was measured by high sensitivity 175 
particle enhanced immunonephelometric assay (Siemens CardioPhase hsCRP) using a 176 
Siemens Dade Behring BNII Nephelometer. Participants with CRP values >10mg/L 177 
indicative of acute infection28 were not included in the analysis (90 from EUREYE and 51 178 
from Cambridge). CRP concentration was natural logarithmically transformed to ensure 179 
normality of the distribution, and further Z transformed for investigation of the association of 180 
a one standard deviation (SD) increase in log CRP with AMD.  181 
 182 
Genotyping 183 
We chose four common SNPs (rs1205, rs1130864 and rs1800947 in the 3’ UTR, and 184 
synonymous rs3093077 in exon 2) in the CRP gene previously reported in a meta-analysis on 185 
CRP and coronary heart disease using a MR approach.17 These variants were selected as the 186 
most parsimonious set of tagging SNPs capturing maximum haplotype diversity and of 187 
demonstrated association with CRP concentrations among subjects of European descent.21,29 188 
The EUREYE samples were genotyped at LGC Genomics (Hoddesdon, United Kingdom) 189 
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using KASPar chemistry, a competitive allele specific polymerase chain reaction (PCR) SNP 190 
genotyping system using FRET quencher cassette oligos. Genotyping in the Cambridge AMD 191 
study was carried out using the ABI PRISM SNaPshot ddNTP Primer Extension Kit and a 192 
3100 Genetic Analyser (Applied Biosystems, Foster City, CA). Genotyping in the MEH 193 
AMD study was carried out using a Taqman (ABI) assay (Applied Biosystems, Foster City, 194 
CA). Departure from Hardy-Weinberg equilibrium was assessed for all SNPs in control 195 
participants using a 2 goodness-of-fit test. 196 
 197 
Statistical association analysis 198 
We investigated the association of CRP genotype with late AMD and by late AMD 199 
phenotype (GA, nvAMD). We also report results for early AMD (available in the EUREYE 200 
study only). All association analyses were conducted as two-stage, fixed-effects meta-201 
analysis of the available individual participant data from the three studies. Heterogeneity 202 
across study centres was assessed using the I2 statistic. We calculated odds ratios (OR) and 203 
their corresponding 95% confidence intervals (CI) using logistic regression models adjusted 204 
for sex and age. ORs were expressed as per one minor allele (multiplicative genetic model). 205 
In order to confirm that, in our study population, the selected SNP genotypes influence 206 
circulating CRP concentrations, we examined the association of CRP genotype with CRP 207 
concentration in controls via a Wald test on the genotype coded as 0, 1, 2 according to the 208 
number of minor alleles using linear regression models adjusted for age and sex. We report 209 
geometric means with standard deviations (SD) for concentrations by genotype. 210 
For comparison with previous studies, we analysed the association of CRP concentration with 211 
late AMD and late AMD phenotype using logistic regression models. These analyses were 212 
adjusted for age and sex and additionally for a priori confounders including history of 213 
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myocardial infection or stroke (CVD), diabetes and smoking. ORs were expressed as per one 214 
SD change of log CRP concentration. 215 
All statistical analyses were conducted using Stata software (Version13.1, Stata Corp LP 216 
College Station, Texas, USA) and ipdmetan and mvmeta commands were used for 217 
conducting meta-analyses of individual participant data. 218 
Results 219 
Characteristics of participants and genotype frequencies by study are shown in Table1. 220 
Genotyping of rs3093077 failed in the EUREYE study and rs1800947 was not typed in the 221 
MEH and Cambridge AMD studies. In each study, no deviation from Hardy-Weinberg 222 
equilibrium was observed for any SNP and control minimum allele frequencies (MAF) were 223 
similar both between studies and to those reported for European ancestry in the HapMap 224 
CEU samples: rs1205 MAF (T) (0.34), rs1130864 MAF (T) (0.31), rs3093077 MAF (G) 225 
(0.05), rs1800947 MAF (C) (0.07). There were significant associations in the pooled analysis 226 
for rs1205 T allele with lower CRP concentration (p=0.001) and for rs1130864 T allele with 227 
higher CRP (p=0.014) in controls (Table 2). For the two rare SNPs rs3093077 and rs1800947 228 
there was no association with CRP concentrations in controls. 229 
 230 
There was no evidence of any association of CRP SNPs rs1205, rs1130864 or rs3093077 231 
with late AMD, or with type of late AMD, either from the individual studies or in the meta-232 
analysis, or for SNP rs1800947 in the EUREYE study (Table 3).  233 
 234 
A significant association was observed in the pooled age and sex adjusted analysis of CRP 235 
concentration with late AMD (Table 4). Additional adjustment for smoking, CVD and 236 
diabetes slightly reduced the ORs (from 1.19 to 1.16) and the p value went from 0.03 to 0.07. 237 
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Analyses of CRP concentration by type of late AMD were OR=1.35, 95% CI (1.03-1.76), 238 
p=0.03 for GA and 1.09 (0.91-1.29), p=0.36 for nvAMD. 239 
  240 
Only the EUREYE study had population based data available on early AMD. There was no 241 
association of CRP concentration with early AMD, in age and sex adjusted or fully adjusted 242 
analyses, OR=1.01, 95% CI (0.82-1.25), p=0.90 or of any CRP SNPs with early AMD, OR 243 
(95% CI) p values for a multiplicative genetic model were: rs1205, OR=1.08 (0.98-1.20) 244 
p=0.13; rs1130864, OR=0.89 (0.75-1.06), p=0.20; rs1800947, OR=1.20 (0.89-1.63), p=0.23. 245 
Discussion 246 
In this meta-analysis of three studies of AMD including 1727 cases with late AMD and 1153 247 
controls, we found no evidence from analysis of CRP variants to support a causal association 248 
of CRP concentration with late AMD, either nvAMD or GA.  249 
 250 
In agreement with many other studies,17,18,30 we found that the T allele of rs1205 was 251 
associated with lower CRP concentrations in controls. However there was no protective 252 
association between the T allele and either nvAMD or GA in any of the three studies. 253 
Similarly the T allele of rs1130864 was associated with higher CRP17 concentrations in 254 
controls but the T allele was not associated with higher odds of either late AMD phenotype.   255 
 256 
None of the three previous studies that investigated CRP polymorphisms and AMD have 257 
found an association.22-24 These studies had smaller sample size than our investigation and 258 
included two23 or three22,24 of the SNPs we investigated (rs1205, rs1130864, rs1800947). In a 259 
case-control study (111 mixed early and late cases and 401 controls) nested within the 260 
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prospective follow-up of the Physicians Health Study, AMD risk was not influenced by any 261 
of seven CRP SNPs24 nor for any of nine CRP SNPs in a sib-pair study of 112 cases of 262 
nvAMD.22 The Rotterdam study (5,861 subjects, of whom 171 late cases) suggested that CRP 263 
haplotypes may modify the association of CFH Y402H genotype with late AMD but the CRP 264 
haplotypes did not influence AMD risk directly; results were not presented for the three CRP 265 
SNPs individually.23 Additionally, a meta-analysis of 15 genome-wide association studies 266 
(GWAS)31 and a recent large GWAS (16,144 cases and 17,832 controls) of AMD did not 267 
show any genome-wide significant association signals at the CRP locus.32 268 
 269 
In our fully adjusted association analyses between CRP concentration and AMD, we did not 270 
find a significant association  with all late AMD (p=0.07; 1,324 subjects, of whom 489 cases) 271 
and nvAMD (p=0.36; 318 cases) or with early AMD (p=0.90; 574 cases) which has been 272 
reported in other studies.9,15,33 The association with AMD is not consistent, particularly in 273 
studies investigating early AMD.11,34-37 In a large meta-analysis comparing low (<1mg/L) 274 
versus high (>3mg/L) CRP concentrations (SI units (<9.5 nmol/L) (>28.6nmol/L), Hong et 275 
al.14 reported an OR of 1.30 (95% CI 1.03-1.65) in three studies that combined early and late 276 
AMD (including 4,522 subjects, of whom 1,629 cases), and an OR of 2.19 (95% CI 1.38-277 
3.47) in eight studies of late AMD (including 35,168 subjects, of whom 1,603 cases). 278 
Estimates for late AMD varied considerably according to method of AMD ascertainment 279 
with much higher ORs reported for clinical diagnosis (OR=3.8) compared to fundus 280 
photography (OR=1.4), adjustment for diabetes (OR=1.6) compared to no adjustment 281 
(OR=2.5) and study design. Population-based cross-sectional or case-control studies had 282 
lower ORs than clinic case-control studies or longitudinal studies. In a pooled analysis of 283 
prospective nested case-control studies from five population based US cohorts (647 cases of 284 
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whom 190 were nvAMD), concentrations of CRP >3mg/L compared to <1mg/L were 285 
associated with risk of all late AMD and nvAMD.15  286 
 287 
While our study was larger than the three previous studies that investigated the relationship 288 
between CRP variants and AMD, it does have a number of limitations, especially with 289 
respect to the relationship between CRP concentration and AMD. In the EUREYE and 290 
Cambridge studies, blood used for measuring CRP concentration was collected at the same 291 
time as ascertainment of AMD and therefore we cannot exclude reverse causation, i.e., an 292 
inflammatory response, for example due to risk factors for AMD such as atherosclerosis and 293 
cardiovascular disease.  We only had one measure of CRP and this may not represent longer-294 
term usual concentrations. Additionally, circulating CRP may not adequately reflect the CRP 295 
concentration in the relevant tissues. It is notable that the monomeric form of CRP (mCRP) 296 
has been shown to be responsible for upregulation of proinflammatory cytokines, IL-8 and 297 
CCL2 in retinal pigment epithelial cells and that patients with AMD carrying the risk variants 298 
of CFH Y204H showed impaired binding of mCRP.38  299 
 300 
Genetic variants in CRP are not subject to reverse causation19,21 and therefore provide 301 
stronger evidence on the possible association of CRP concentration with AMD. We 302 
investigated only a small number of CRP SNPS. Nevertheless, we selected SNPs expected to 303 
show a causal relationship with AMD, since these SNPs influence CRP 304 
concentrations.17,20,21,29 Variants associated with CRP concentrations in other loci have been 305 
identified in large GWAS and replication studies.18,39  These variants are in genes primarily 306 
involved in lipid, metabolic or immune pathways and include IL6R, HNF1A, APOCI.  In a 307 
GWAS of coronary heart disease (CHD) the APOC1 variant (rs4420638) was associated with 308 
increased risk of CHD but in an opposite direction to that predicted from its relationship with 309 
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CRP and consistent with its effects on LDL and HDL cholesterol and triglycerides.18 This 310 
variant has also been identified at genome-wide significance to increase AMD risk.31 APOC1 311 
is part of the apolipoprotein gene cluster which plays a major role in lipid transport and 312 
metabolism and includes the well established APOE AMD risk variant (rs429358).40 Linkage 313 
Disequilibrium (r2=0.7) is observed between rs4420638 and rs429358 in the EUR 314 
populations from the Phase 3 of the 1000 Genomes Project 315 
(http://analysistools.nci.nih.gov/LDlink accessed Oct 3rd 2016).  316 
 317 
In summary, from the analogy with CHD17 and the identification of alternate genetic loci for 318 
CRP concentrations discussed above, along with the lack of association of variants in the 319 
CRP locus with AMD shown in our meta-analysis corroborating results from previous 320 
studies, we conclude that CRP concentration is unlikely to be causally related to AMD. 321 
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Table 1. Demographic, C-reactive protein (CRP) concentration and CRP SNP genotype frequencies by study. 322 
 EUREYE Cambridge MEH 
 Controls Early AMD Late AMD Controls Late AMD Controls Late AMD 
N 643 574 152 262 427 245 1145 
Age1 74.7 (6.1) 74.6 (5.9) 79.5 (7.2) 75.7 (7.8) 80.4 (6.9) 74.8 (8.0) 77.9 (7.4) 
Male (%) 46.8 48.6 34.2 40.1 45.9 41.9 36.6 
CRP2 1.88 (1.21) 1.99 (1.35) 1.90 (1.28) 1.84 (1.72) 2.15 (1.92) Not available    
rs1205         
CC  273 (44.6) 246 (43.9) 58 (39.7) 119 (46.5) 200 (47.7) 101 (43.7) 478 (44.1) 
CT 267 (43.6) 240 (42.9) 75 (51.4) 113 (44.1) 183 (43.7) 107 (46.3) 507 (46.8) 
TT 72 (11.8) 74 (13.2) 13 (8.9) 24 (9.4) 36 (8.6) 23 (10.0) 99 (9.1) 
Total 612 560 146 256 419 231 1084 
HWE3 0.36   0.70  0.49  
MAF4 0.35   0.31  0.33  
rs1130864        
CC 280 (45.9) 265 (47.6) 68 (46.3) 126 (48.1) 188 (44.4) 104 (44.6) 528 (48.7) 
CT 266 (43.6) 245 (44.0) 68 (46.3) 113 (43.1) 204 (48.2) 108 (46.4) 451 (41.6) 
TT 64 (10.5) 47 (8.4) 11 (7.4) 23 (8.8) 31 (7.3) 21 (9.0) 105 (9.7) 
Total 610 557 147 262 423 233 1084 
HWE3 0.73   0.74  0.35  
MAF4 0.35   0.30  0.32  
rs3093077 Failed     
TT    232 (88.5) 380 (89.4) 211 (90.6) 960 (88.5) 
GT    30 (11.5) 45 (10.6) 21 (9.0) 119 (11.0) 
GG    0 0 1 (0.4) 6 (0.5) 
Total    262 425 233 1085 
HWE3    0.33  0.55  
MAF4    0.06  0.05  
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 323 
 324 
 325 
 326 
 327 
 328 
1 Mean (Standard Deviation) 329 
2 Geometric mean (Standard Deviation) (mg/dL) 330 
3 Hardy Weinberg Equilibrium p value 331 
4 Minimum Allele Frequency 332 
 333 
rs1800947    Not available Not available 
GG 519 (88.7) 471 (87.4) 113 (83.1)     
CG 63 (10.8) 65 (12.1) 21 (15.4)     
CC 3 (0.5) 3 (0.6) 2 (1.5)     
Total 585 539 136     
HWE3 0.50       
MAF4 0.07       
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Table 2. C-reactive protein (CRP) concentration by genotypes of CRP SNPs in controls. 334 
 335 
 336 
 337 
 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
 347 
 348 
 349 
 350 
 351 
 352 
 353 
1 Geometric mean (Standard Deviation) mg/dL 354 
2 p value from per allele regression model of age and sex adjusted log serum CRP in each study  355 
3 p value from per allele regression model of age and sex adjusted log serum CRP in meta-analysis  356 
 EUREYE Cambridge 
CRP SNPs N CRP1 N CRP1 
rs1205     
CC  255 2.05 (1.36) 105 1.97 (1.83) 
TC   249 1.79 (1.10) 96 1.82 (1.77) 
TT  67 1.65 (1.01) 21 1.28 (1.25) 
p2  0.003  0.128 
p pooled3 0.001 
     
rs1130864     
CC   264 1.87 (1.24) 110 1.43 (1.42) 
TC  248 1.84 (1.09)  94 2.32 (2.11) 
TT  56 2.26 (1.65) 21 2.19 (1.29) 
p2  0.185  0.002 
p pooled3 0.014 
     
rs3093077     
TT   200 1.82 (1.72) 
GT   25 1.83 (1.91) 
GG   0  
p2    0.829 
     
rs1800947     
GG  486 1.87 (1.20)   
GC   56 2.15 (1.30)   
CC 3 1.11 (0.74)   
p2  0.455   
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Table 3. Association of CRP SNPS with late AMD in the EUREYE, Cambridge and MEH AMD studies. 357 
 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
1 Sex- and age-adjusted Odds Ratio (OR), 95% Confidence Interval (CI) and p value for a genetic multiplicative model.  370 
 EUREYE Cambridge MEH Pooled 
 OR (95% CI) p value1 OR (95% CI) p value1 OR (95% CI) p value1 OR (95% CI) p value1 
Late AMD     
rs1205 1.06 (0.80-1.40) p=0.69 0.95 (0.73-1.22) p=0.66 0.98 (0.78-1.23) p=0.87 0.99 (0.86-1.14) p=0.88 
rs1130864 0.86 (0.64-1.16) p=0.33 1.17 (0.90-1.52) p=0.24 0.89 (0.71-1.11) p=0.29 0.96 (0.83-1.11) p=0.60 
rs3093077 Not available 0.92 (0.55-1.54) p=0.76 1.26 (0.80-1.98) p=0.32 1.10 (0.78-1.55) p=0.59 
rs1800947 1.54 (0.95-2.50) p=0.08 Not available Not available  
      
Neovascular AMD     
rs1205 1.04 (0.75-1.44) p=0.81 0.99 (0.76-1.30) p=0.96 1.02 (0.80-1.29) p=0.88 1.01 (0.87-1.19) p=0.85 
rs1130864 0.83 (0.58-1.17) p=0.28 1.29 (0.97-1.71) p=0.08 0.90 (0.71-1.13) p=0.35 0.99 (0.84-1.16) p=0.86 
rs3093077 Not available 1.02 (0.59-1.77) p=0.95 1.25 (0.78-2.01) p=0.35 1.15 (0.80-1.64) p=0.45 
rs1800947 1.68 (0.97 -2.93) p=0.06 Not available Not available  
     
Geographic Atrophy     
rs1205 1.11 (0.71-1.74) p=0.65 0.91 (0.60-1.38) p=0.65 0.85 (0.64-1.13) p=0.26 0.91 (0.74-1.13) p=0.40 
rs1130864 0.98 (0.61-1.60) p=0.95 1.18 (0.79-1.76) p=0.42 0.83 (0.62-1.10) p=0.20 0.94 (0.76-1.16) p=0.59
rs3093077 Not available 0.73 (0.29-1.84) p=0.51 1.62 (0.94-2.77) p=0.08 1.31 (0.83-2.10) p=0.25 
rs1800947 1.37 (0.62-3.04) p=0.43 Not available Not available  
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Table 4. Association of C-Reactive protein (CRP) concentration with late age-related macular degeneration (AMD). 371 
 Late AMD Neovascular AMD Geographic Atrophy 
 EUREYE
  
Cambridge Pooled 
N=1324 
EUREYE Cambridge Pooled 
N=1153 
EUREYE Cambridge Pooled 
N=946 
OR1,2 1.17 1.20 1.19 1.09 1.13 1.12 1.33 1.48 1.43 
95% CI 0.89-1.56 1.00-1.45 1.02-1.39 0.79- 1.51 0.93-1.38 0.95-1.33 0.84-2.09 1.09-2.02 1.11-1.84 
p3    0.026   0.189   0.006 
          
OR4 1.10 1.18 1.16 1.00 1.12 1.09 1.26 1.39 1.35 
95% CI 0.82-1.47 0.98-1.43 0.99-1.36 0.71-1.41 0.91-1.37 0.91-1.29 0.79-2.03 1.01-1.92 1.03-1.76 
p    0.068   0.361   0.029 
 372 
1 Odds Ratio per Standard Deviation change in log CRP concentration 373 
2 adjusted for age and sex   374 
3 p value from meta-analysis of EUREYE and Cambridge 375 
4 adjusted for age, sex, diabetes, cardiovascular disease, smoking 376 
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